MedTrace Logo

Application of QDSA Platform in Cerebrovascular Diseases

NCT06902415 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-03-30

No results posted yet for this study

Summary

Cerebrovascular diseases pose a major global public health challenge, characterized by exceptionally high mortality and disability rates, with their pathogenesis closely linked to hemodynamic abnormalities. The quantitative digital subtraction angiography (QDSA) analysis platform, leveraging its advantages of vessel modeling-free operation, high computational efficiency, and DSA-equivalent sensitivity, has emerged as a novel hemodynamic assessment method with significant clinical potential. This study aims to establish a cerebrovascular disease cohort incorporating QDSA parameters to systematically validate the clinical value of this technology in preoperative evaluation and surgical planning, thereby providing evidence-based insights for optimizing diagnostic and therapeutic strategies.

Conditions

  • Cerebrovascular Disease

Interventions

DEVICE

QDSA (Quantitative Digital Subtraction Angiography)

QDSA is a quantitative analysis technology based on DSA, used to assess hemodynamic characteristics and provide critical data support for the diagnosis and treatment of cerebrovascular diseases.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2030-02-28
Completion
2030-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06902415 on ClinicalTrials.gov